CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07043608
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:38.468424+00:00
Published At: 2025-07-02T00:00:00+00:00
Record Updated At: 2025-07-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Clear Cell Renal Cell Cancer (ccRCC)", "Clear Cell Renal Carcinoma", "Clear Cell Renal Cell Carcinoma Metastatic", "Clear Cell Renal Cancer", "Bone Metastases of a Malignant Tumor", "Clear Cell Renal Cell Carcinoma", "Bone, Metastatic Cancer", "Metastatic Cancer", "Metastatic Renal Cell Carcinoma", "Metastases to Bone"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-07-02"
protocolSection.identificationModule.nctId: "NCT07043608"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.